<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95662">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01756456</url>
  </required_header>
  <id_info>
    <org_study_id>NGF0212</org_study_id>
    <secondary_id>2012-002527-15</secondary_id>
    <nct_id>NCT01756456</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.</brief_title>
  <acronym>REPARO</acronym>
  <official_title>An 8-week Phase I/II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study With a 48 or 56 Week Follow-up Period to Evaluate the Safety and Efficacy of Two Doses (10 µg/ml and 20 µg/ml) of Recombinant Human Nerve Growth Factor Eye Drops Solution Versus Vehicle in Patients With Stage 2 and 3 of Neurotrophic Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dompé s.p.a.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dompé s.p.a.</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Hungary: Institutional Ethics Committee</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>Portugal: Health Ethic Committee</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at assessing the safety and the efficacy of two dose regimens of
      recombinant human nerve growth factor (rhNGF) eye drops solution compared to vehicle for
      inducing a complete healing of stage 2 (persistent epithelial defect) and 3 (corneal ulcer)
      neurotrophic keratitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the safety and the efficacy of two dose
      regimens (10 µg/ml or 20 µg/ml 6 times a day) of recombinant human nerve growth factor
      (rhNGF) eye drops solution compared to vehicle for inducing a complete healing of stage 2
      (persistent epithelial defect) and 3 (corneal ulcer) neurotrophic keratitis (NK) as measured
      by the investigator using corneal fluorescein staining Secondary objectives of the study are
      to assess the duration of complete healing, improvement in visual acuity and improvement in
      corneal sensitivity following treatment with rhNGF eye drops solution

      This is a combined phase I/II study. The  phase I and II segments of the study will be
      conducted as an 8 week, randomized, double-masked, vehicle controlled, parallel group study
      (referred to as the  controlled treatment period) followed by a 48 or 56 week  follow-up
      period The design of the phase I and phase II segments of the study are identical with the
      exception that in the phase I segment of the study the randomization scheme is different and
      patients will be followed with additional safety assessments and blood samples for PK
      (pharmacokinetic) profiling In the ascending dose Phase I segment of the study two doses of
      rhNGF 10 and 20 µg/ml will be evaluated in a sequential manner
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete healing of the persistent epithelial defect or corneal ulcer</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients achieving  complete healing of the PED or corneal ulcer determined by  corneal fluorescein staining at 4 weeks as defined by the investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients experiencing complete healing of the persistent epithelial defect or corneal</measure>
    <time_frame>After 6 weeks after start of the treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients experiencing complete healing of the PED or corneal ulcer at 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients experiencing complete healing of the persistent epithelial defect or corneal</measure>
    <time_frame>After 8 weeks after start of the treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients experiencing complete healing of the PED or corneal ulcer at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Anti-NGF antibodies</measure>
    <time_frame>At screening and at week 8</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Anti-NGF antibodies and laboratory tests are performed at screening and at the end of treatment and shift tables will be used to present shifts from within/outside the normal range between screening and end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ocular tolerability</measure>
    <time_frame>Weeks 2, 4, 6 and 8</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Ocular tolerability as measured by the visual analogue scale (VAS) will be analyzed by means of analysis of variance, including terms for treatment, time (Weeks 2, 4, 6 and 8), and treatment by time interaction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Neurotrophic Keratitis</condition>
  <condition>Keratitis</condition>
  <condition>Corneal Ulcer</condition>
  <arm_group>
    <arm_group_label>rhNGF 10µg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhNGF 10 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNGF 20 µg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhNGF 20 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 10 µg/ml eye drops solution</intervention_name>
    <description>rhNGF 10 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
    <arm_group_label>rhNGF 10µg/ml</arm_group_label>
    <other_name>recombinant human nerve growth factor 10 µg/ml solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 20 µg/ml eye drops solution</intervention_name>
    <description>rhNGF 20 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
    <arm_group_label>rhNGF 20 µg/ml</arm_group_label>
    <other_name>recombinant human nerve growth factor 20 µg/ml solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only.</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years of age or older.

          2. Patients with stage 2 (persistent epithelial defect, PED) or stage 3 (corneal ulcer)
             neurotrophic keratitis involving only one eye. . Patients with Controlateral eye
             affected with stage 1 NK can be enrolled.

          3. PED or corneal ulceration of at least 2 weeks duration refractory to one or more
             conventional non-surgical treatments for neurotrophic keratitis (e.g.,
             preservative-free artificial tears, gels or ointments; discontinuation of preserved
             topical drops and medications that can decrease corneal sensitivity; therapeutic
             contact lenses).

          4. Evidence of decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet
             aesthesiometer) within the area of the PED or corneal ulcer and outside of the area
             of the defect in at least one corneal quadrant.

          5. Best corrected distance visual acuity (BCDVA) score ≤ 75 ETDRS letters, (≥ 0.2
             LogMAR, ≤ 20/32 Snellen or ≤ 0.625 decimal fraction) in the affected eye.

          6. No objective clinical evidence of improvement in the PED or corneal ulceration within
             the 2 weeks prior to study enrolment.

          7. Only patients who satisfy all Informed Consent requirements may be included in the
             study. The patient and/or his/her legal representative must read, sign and date the
             Informed Consent document before any study-related procedures are performed. The
             Informed Consent form signed by patients and/or legal representative must have been
             approved by the IEC/IRB for the current study.

          8. Patients must have the ability and willingness to comply with study procedures.

          9. Patients must be eligible for the National Health Insurance (where applicable).

        Exclusion Criteria:

          1. Patients with stage 2 or 3 NK affecting both eyes.

          2. Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular
             inflammation not related to NK in the affected eye.

          3. Any other ocular disease requiring topical ocular treatment in the affected eye
             during the course of the study treatment period. No topical treatments other than the
             study medications provided by the study sponsor or  allowed by the study protocol can
             be administered in the affected eye during the course of the study treatment periods.

          4. Patients with severe vision loss in the affected eye with no potential for visual
             improvement in the opinion of the investigator as a result of the study treatment.

          5. Schirmer test without anesthesia ≤3 mm/5 minutes in the affected eye.

          6. Patients with severe blepharitis and/or severe meibomian gland disease in the
             affected eye.

          7. History of any ocular surgery (including laser or refractive surgical procedures) in
             the affected eye within the three months before study enrolment. (An exception to the
             preceding statement will be allowed if the ocular surgery is considered to be the
             cause of the stage 2 or 3 NK). Ocular surgery in the affected eye will not be allowed
             during the study treatment period and elective ocular surgery procedures should not
             be planned during the duration of the follow-up period.

          8. Prior surgical procedure(s) for the treatment of NK (e.g. complete tarsorraphy,
             conjunctival flap, etc) in the affected eye with the exception of amniotic membrane
             transplantation. Patients previously treated with amniotic membrane transplantation
             may only be enrolled two weeks after the membrane has disappeared within the area of
             the PED or corneal ulcer or at least six weeks after the date of the amniotic
             membrane transplantation procedure.  Patients previously treated with Botox
             (botulinum toxin) injections used to induce pharmacologic blepharoptosis are eligible
             for enrolment only if the last injection was given at least 90 days prior to
             enrolment in the study.

          9. Use of therapeutic contact lenses or contact lens wear for refractive correction
             during the study treatment periods in the eye with NK.

         10. Anticipated need for punctual occlusion during the study treatment period.  Patients
             with punctual occlusion or punctual plugs inserted prior to the study are eligible
             for enrolment provided that the punctual occlusion is maintained during the study.

         11. Evidence of corneal ulceration involving the posterior third of the corneal stroma,
             corneal melting or perforation in the affected eye.

         12. Presence or history of any ocular or systemic disorder or condition that might hinder
             the efficacy of the study treatment or its evaluation, could possibly interfere with
             the interpretation of study results, or could be judged by the investigator to be
             incompatible with the study visit schedule or conduct (e.g. progressive or
             degenerative corneal or retinal conditions, uveitis, optic neuritis, poorly
             controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases).

         13. Any need for or anticipated change in the dose of systemic medications known to
             impair the function of the trigeminal nerve (e.g. neuroleptics, antipsychotic and
             antihistamine drugs). These treatments are allowed during the study if initiated
             prior to 30 days before study enrolment provided they remain stable throughout the
             course of the study treatment periods.

         14. Known hypersensitivity to one of the components of the study or procedural
             medications (e.g. fluorescein).

         15. History of drug, medication or alcohol abuse or addiction.

         16. Use of any investigational agent within 4 weeks of screening visit.

         17. Participation in another clinical study at the same time as the present study.

         18. Females of childbearing potential (those who are not surgically sterilized or
             post-menopausal for at least 1 year) are excluded from participation in the study if
             they meet any one of the following conditions: are currently pregnant or have a
             positive result on the urine pregnancy test at the Randomization Visit or intend to
             become pregnant during the study treatment period or are breast-feeding or not
             willing to use highly effective birth control measures, such as: Hormonal
             contraceptives -oral, implanted, transdermal, or injected and/or Mechanical barrier
             methods -spermicide in conjunction with a barrier such as a condom or diaphragm or
             IUD during the entire course of and 30 days after the study treatment periods.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Sinigaglia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dompé s.p.a., Milan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabella Filatori, M.Sc.</last_name>
    <phone>00390258383205</phone>
    <email>isabella.filatori@dompe.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paolo Battigello, M.Sc.</last_name>
    <phone>00390258383422</phone>
    <email>paolo.battigello@dompe.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen - Dienst Oftalmologie</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Koppen, MD</last_name>
      <phone>+3238213372</phone>
      <email>carina.koppen@uza.be</email>
    </contact>
    <investigator>
      <last_name>Carina Koppen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - Service ophtalmologie</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Creuzot Garchet, MD</last_name>
    </contact>
    <investigator>
      <last_name>Catherine Creuzot Garchet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren - Service Ophtalmologie</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Pierre-Yves, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-Yves Robert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier National d'Ophtalmologie - Service d'ophtalmologie</name>
      <address>
        <city>Paris</city>
        <zip>75 571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Borderie, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Borderie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Fondation Ophtalmologique Adolphe de Rothschild - &quot;Unité de Recherche Clinique</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric \ Gabison, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Gabison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;CHU Toulouse-Purpan - Service Ophtalmologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Malecaze, MD</last_name>
    </contact>
    <investigator>
      <last_name>François Malecaze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Eye Clinic in Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerd Geerling, MD</last_name>
      <email>gerd.geerling@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Gerd Geerling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedrich E Kruse, MD</last_name>
      <email>heidrun.mueller-betz@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Friedrich E Kruse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Augenklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Böhringer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Böhringer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität zu Köln - Zentrum für Augenheilkunde am Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Cursiefen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claus Cursiefen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes-Gutenberg-Universität Augenklinik und Poliklinik - Department of Ophthalmology</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Lorenz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Katrin Lorenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München - Augenklinik der Ludwig-Maximilians-Universtiät München</name>
      <address>
        <city>Munchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Messmer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth Messmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>H-1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janos Nemeth, MD</last_name>
      <email>nj@szem1.sote.hu</email>
    </contact>
    <investigator>
      <last_name>Janos Nemeth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSPEDALE SAN RAFFAELE di Milano</name>
      <address>
        <city>Milan</city>
        <state>Lombardy</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulio Ferrari, MD</last_name>
      <phone>00390226433598</phone>
      <email>ferrari.giulio@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Oriella Ambrosio, MD</last_name>
      <phone>00390226433598</phone>
      <email>ambrosio.oriella@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giulio Ferrari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Rama, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oriella Ambrosio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università G. D' Annunzio - Clinica Oftalmologica - Centro regionale di Eccellenza in Oftalmologia</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Mastropasqua, MD</last_name>
    </contact>
    <investigator>
      <last_name>Leonardo Mastropasqua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Mencucci, MD</last_name>
      <email>rita.mecucci@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Ugo Menchini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Mencucci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Neurologiche Oftalmologia e Genetica - Universtità di Genova</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Rolando, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maurizio Rolando, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Messina - Dipartimento Specialità Chirurgiche Ambulatorio Studio delle Malattie dela Superficie Oculare Unità Operativa Complessa di Oftalmologia</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pasquale Aragona, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pasquale Aragona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Paolo - U.O. Oculistica</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Fogagnolo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Fogagnolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera di Padova - Clinica Oculistica Policlinico 7° Piano</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Leonardi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Leonardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Campus Bio-Medico di Roma</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavio Mantelli, MD</last_name>
      <email>f.mantelli@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Bonini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Flavio Mantelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>District Railway Hospital Katowice - Department of Ophthalmology</name>
      <address>
        <city>Katowice</city>
        <zip>40-760</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Wylegala, MD</last_name>
    </contact>
    <investigator>
      <last_name>Edward Wylegala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;SPKSO Szpital Okulistyczny ul. - SPKSO Szpital Okulistyczny</name>
      <address>
        <city>Warsawa</city>
        <zip>03-709</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek P Szaflik, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jacek P Szaflik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Coimbra, EPE - Department Ophthalmology</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquim C Neto Murta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joaquim C Neto Murta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de São João - Department Ophthalmology</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Torrao, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luis Torrao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vissum Corporación Oftalmológica de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Alio</last_name>
      <email>jlalio@vissum.com</email>
    </contact>
    <investigator>
      <last_name>Jorge Alio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces - Oftalmología</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Echevarría, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jaime Echevarría, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona - Oftalmología</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maite Sainz de la Maza, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maite Sainz de la Maza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos - Oftalmología. Unidad de Superficie Ocular</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José M Benitez del Castillo, MD</last_name>
    </contact>
    <investigator>
      <last_name>José M Benitez del Castillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico Fernández-Vega - Oftalmología</name>
      <address>
        <city>Oviedo, Asturias</city>
        <zip>33012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Merayo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jesus Merayo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cartuja Visión - Oftalmología</name>
      <address>
        <city>Sevilla</city>
        <zip>41092</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Montero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jesus Montero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Birmingham - Academic Unit of Ophthalmology, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>&quot;B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saaeha Rauz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Saaeha Rauz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Garthnavel General Hospital - Tennent Institute of Ophthalmology</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kanna Ramaesh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kanna Ramaesh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital - Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Dart, MD</last_name>
    </contact>
    <investigator>
      <last_name>John Dart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Eye Hospital - Manchester Royal Eye Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Carley, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fiona Carley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary - Dept. of Ophthalmology</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Figueiredo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francisco Figueiredo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southampton Southampton General Hospital - MP104, Eye Unit</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parwez Hossain, MD</last_name>
    </contact>
    <investigator>
      <last_name>Parwez Hossain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>December 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keratitis</keyword>
  <keyword>Corneal Ulcer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Corneal Ulcer</mesh_term>
    <mesh_term>Keratitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
